Literature DB >> 15297270

Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis.

Peter M Hopkins1, Christina L Aboyoun, Prashant N Chhajed, Monique A Malouf, Marshall L Plit, Stephen P Rainer, Allan R Glanville.   

Abstract

The clinical significance of minimal acute rejection (grade A1) in lung transplant recipients is unknown. We prospectively analyzed 1,159 transbronchial lung biopsies in 184 patients. Two hundred seventy-nine biopsies in 128 participants confirmed A1 histology at a mean postoperative day of 229 +/- 340. Sixty four of 255 surveillance A1 lesions progressed to high-grade acute rejection by 3 months of follow-up, whereas 40 developed new lymphocytic bronchiolitis. Twenty-four A1 biopsies were symptomatic, with only two cases progressing to high-grade rejection after steroid therapy. Seventy-eight of 184 patients experienced multiple (> or = 2) A1 biopsies in the first 12 months after transplant. Bronchiolitis obliterans syndrome developed in 68% of patients with multiple A1 lesions at a mean of 599 +/- 435 days, compared with 43% of patients with one or less A1 lesions at a mean of 819 +/- 526 (p = 0.022). Eighteen patients experienced multiple A1 biopsies after transplant in the absence of high-grade rejection episodes yet also developed earlier obliterative bronchiolitis (456 +/- 245 days, p = 0.020). We conclude that for A1 transbronchial lung biopsies, the conventional treatment of observation only is now challenged even in patients who are asymptomatic. Patients who experience multiple A1 lesions develop an earlier onset of obliterative bronchiolitis and may warrant alternative immunosuppressive strategies.

Entities:  

Mesh:

Year:  2004        PMID: 15297270     DOI: 10.1164/rccm.200302-165OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

Review 1.  Immunosuppression and allograft rejection following lung transplantation: evidence to date.

Authors:  Gregory I Snell; Glen P Westall; Miranda A Paraskeva
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies.

Authors:  Andrew I R Scott; Linda D Sharples; Susan Stewart
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Imaging mouse lung allograft rejection with (1)H MRI.

Authors:  Jinbang Guo; Howard J Huang; Xingan Wang; Wei Wang; Henry Ellison; Robert P Thomen; Andrew E Gelman; Jason C Woods
Journal:  Magn Reson Med       Date:  2014-06-20       Impact factor: 4.668

Review 4.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

5.  Acute rejection after lung transplantation: association between histopathological and CT findings.

Authors:  Ambra Di Piazza; Giuseppe Mamone; Settimo Caruso; Gianluca Marrone; Fabio Tuzzolino; Patrizio Vitulo; Alessandro Bertani; Roberto Miraglia
Journal:  Radiol Med       Date:  2019-07-05       Impact factor: 3.469

6.  Staphylococcus via an interaction with the ELR+ CXC chemokine ENA-78 is associated with BOS.

Authors:  A L Gregson; X Wang; P Injean; S S Weigt; M Shino; D Sayah; A DerHovanessian; J P Lynch; D J Ross; R Saggar; A Ardehali; G Li; R Elashoff; J A Belperio
Journal:  Am J Transplant       Date:  2015-02-12       Impact factor: 8.086

Review 7.  Prevention of chronic rejection after lung transplantation.

Authors:  Anke Van Herck; Stijn E Verleden; Bart M Vanaudenaerde; Geert M Verleden; Robin Vos
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

8.  Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.

Authors:  Aric L Gregson; Xiaoyan Wang; S Sam Weigt; Vyacheslav Palchevskiy; Joseph P Lynch; David J Ross; Bernard M Kubak; Rajan Saggar; Michael C Fishbein; Abbas Ardehali; Gang Li; Robert Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

9.  Minimal acute rejection in pediatric lung transplantation--does it matter?

Authors:  Christian Benden; Albert Faro; Sarah Worley; Susana Arrigain; Paul Aurora; Manfred Ballmann; Debra Boyer; Carol Conrad; Irmgard Eichler; Okan Elidemir; Samuel Goldfarb; George B Mallory; Peter J Mogayzel; Daiva Parakininkas; Melinda Solomon; Gary Visner; Stuart C Sweet; Lara A Danziger-Isakov
Journal:  Pediatr Transplant       Date:  2010-01-04

10.  Usefulness of immune monitoring in lung transplantation using adenosine triphosphate production in activated lymphocytes.

Authors:  Michael Y Shino; S Samuel Weigt; Rajan Saggar; David Elashoff; Ariss Derhovanessian; Aric L Gregson; Rajeev Saggar; Elaine F Reed; Bernard M Kubak; Joseph P Lynch; John A Belperio; Abbas Ardehali; David J Ross
Journal:  J Heart Lung Transplant       Date:  2012-09       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.